Search results for "weakness"

showing 10 items of 198 documents

Opioid-induced or pain relief-reduced symptoms in advanced cancer patients?

2006

Abstract Background While opioids in increasing doses may produce adverse effects, the same adverse effects may be associated with poor pain control. Moreover, in the clinical setting symptomatic treatment and illness may balance the outcome of opioid titration. Some adverse effects may tend to disappear continuing the treatment in a long-term period. Aims The aim of this study was to monitor the effects of a rapid opioid titration combined with symptomatic treatment in patients with poor relief and to monitor these changes in the following period of 20 days. Methods A consecutive sample of 35 patients admitted to an acute Pain Relief and Palliative Care Unit were titrated with opioids, acc…

MaleWeaknessPalliative careConstipationNauseaOpioid-induced symptoms; pain relief; advanced cancer patients; longitudinal prospective studymedia_common.quotation_subjectPainpain reliefadvanced cancer patientlongitudinal prospective studyNeoplasmsmedicineHumansLongitudinal StudiesProspective StudiesAdverse effectmedia_commonbusiness.industryPalliative CareAppetiteMiddle AgedAnalgesics OpioidAnesthesiology and Pain MedicineOpioidPatient SatisfactionAnesthesiaEmergency MedicineVomitingFemalemedicine.symptomCancer painbusinessOpioid-induced symptommedicine.drug
researchProduct

Novel missense mutation in the ATP1A2 gene associated with atypical sporapedic hemiplegic migraine

2019

Hemiplegic migraine (HM) is a rare subtype of migraine with aura in which attacks include transient motor weakness or hemiparesis that can last several days. HM is linked to mutations in three different genes, CACNA1A, ATP1A2 and SCN1A, which encode for ion transporters. The clinical spectrum includes atypical symptoms such as impaired consciousness, epileptic seizures, permanent cerebellar ataxia or mental retardation. We describe a novel mutation found in the ATP1A2 gene in a patient with late-onset HM. His attacks were characterised by motor weakness associated with altered mental status, diplopia and ataxia. He also showed up MRI abnormalities and incomplete response to prophylactic the…

MaleWeaknessPediatricsmedicine.medical_specialtyAtaxiaNeurologyMigraine with AuraMutation MissenseNeuroimagingneuro geneticsDiagnosis Differential03 medical and health sciences0302 clinical medicineRare DiseaseATP1A2medicineHumansMissense mutationgenetic screening / counselling030212 general & internal medicineMigraineAgedNeurologic ExaminationGenetic counsellingCerebellar ataxiabusiness.industryHeadacheGeneral MedicineMagnetic Resonance ImagingMigraine with auraPedigreeHemiparesisNeurologySettore MED/26 - NeurologiaSodium-Potassium-Exchanging ATPasemedicine.symptombusinessheadache (including migraines)030217 neurology & neurosurgery
researchProduct

The use of corticosteroids in home palliative care

2001

Evidence for the effectiveness of corticosteroids in palliative care is anecdotal, and more information is required. From January to December 1999 a total of 376 consecutive patients admitted to a home palliative care program were longitudinally surveyed. Patients who started a corticosteroid treatment after admission on the basis of common indications prescribed by their home care physicians were selected. Fifty patients were enrolled in the study. Dexametha-sone, in doses ranging from 4 to 16 mg, was the drug of choice. Corticosteroids were found to be effective in anorexia, weakness, headache, and nausea and vomiting. The reduction of symptom intensity was achieved in less than 3 days on…

MaleWeaknessPediatricsmedicine.medical_specialtyPalliative careNauseaLongitudinal epedemiological studyAnorexiaHome palliative careDexamethasoneStatistics NonparametricmedicineHumansCorticosteroidLongitudinal StudiesAdverse effectIntensive care medicineGlucocorticoidsNursing (all)2901 Nursing (miscellaneous)AgedAged 80 and overbusiness.industryPalliative CareTherapeutic effectMiddle Agedmedicine.diseaseHome Care ServicesBowel obstructionItalyOncologyVomitingFemalemedicine.symptombusiness
researchProduct

Inspiratory Muscle Function and Exercise Capacity in Patients With Heart Failure With Preserved Ejection Fraction

2017

Background: Heart failure with preserved ejection fraction (HFpEF) is a clinical syndrome characterized by impaired exercise capacity resulting from dyspnea and fatigue. The pathophysiological mechanisms underlying the exercise intolerance in HFpEF are not well established. We sought to evaluate the effects of inspiratory muscle function on exercise tolerance in symptomatic patients with HFpEF. Methods and Results: A total of 74 stable symptomatic patients with HFpEF and New York Heart Association class II-III underwent a cardiopulmonary exercise test between June 2012 and May 2016. Inspiratory muscle weakness was defined as maximum inspiratory pressure (MIP) <70% of normal predicted values…

MaleWeaknessmedicine.medical_specialtyExercise intolerance030204 cardiovascular system & hematologyCohort Studies03 medical and health sciences0302 clinical medicineInternal medicineHumansMedicineProspective Studies030212 general & internal medicineProspective cohort studyAgedAged 80 and overHeart FailureExercise ToleranceMuscle Weaknessbusiness.industryMuscle weaknessStroke VolumeStroke volumeMiddle Agedmedicine.diseasePathophysiologyinspiratory muscle functionexercise capacityHeart failure with preserved ejection fractionInhalationHeart failureExercise TestCardiologyFemalemedicine.symptomCardiology and Cardiovascular MedicinebusinessHeart failure with preserved ejection fractionhuman activitiesJournal of Cardiac Failure
researchProduct

Continuous Compared to Accumulated Walking-Training on Physical Function and Health-Related Quality of Life in Sedentary Older Persons

2020

The present study aimed to analyze the impact of overground walking interval training (WIT) in a group of sedentary older adults, comparing two different dose-distributions. In this quasi-experimental and longitudinal study, we recruited twenty-three sedentary older adults (71.00 &plusmn

MaleWeaknessmedicine.medical_specialtyLongitudinal studyHealth Toxicology and Mutagenesisphysical activitylcsh:MedicineWalkingArticleInterval trainingagility test03 medical and health sciencessymbols.namesake0302 clinical medicineQuality of lifemedicineHumansLongitudinal Studies030212 general & internal medicineExerciseolder adultsAgedMorningdose-responseAged 80 and overcardiorespiratory fitnessbusiness.industrypublic healthaginglcsh:RPublic Health Environmental and Occupational HealthCardiorespiratory fitnessPreferred walking speedBonferroni correctionexecutive functionCardiorespiratory FitnessPhysical FitnessQuality of LifesymbolsPhysical therapyFemalemedicine.symptomstrengthbusiness030217 neurology & neurosurgeryInternational Journal of Environmental Research and Public Health
researchProduct

HACD1, a regulator of membrane composition and fluidity, promotes myoblast fusion and skeletal muscle growth

2015

International audience; The reduced diameter of skeletal myofibres is a hallmark of several congenital myopathies, yet the underlying cellular and molecular mechanisms remain elusive. In this study, we investigate the role of HACD1/PTPLA, which is involved in the elongation of the very long chain fatty acids, in muscle fibre formation. In humans and dogs, HACD1 deficiency leads to a congenital myopathy with fibre size disproportion associated with a generalized muscle weakness. Through analysis of HACD1-deficient Labradors, Hacd1-knockout mice, and Hacd1-deficient myoblasts, we provide evidence that HACD1 promotes myoblast fusion during muscle development and regeneration. We further demons…

Male[SPI.GPROC] Engineering Sciences [physics]/Chemical and Process EngineeringCellular differentiationGeneralized muscle weaknessBiologyMuscle Developmentcentronuclear myopathyCell LineMyoblasts03 medical and health scienceschemistry.chemical_compoundMyoblast fusionMice0302 clinical medicineDogsVLCFA[SDV.IDA]Life Sciences [q-bio]/Food engineeringGeneticsmedicineMyocyteAnimalsHumans[SPI.GPROC]Engineering Sciences [physics]/Chemical and Process EngineeringMUFACentronuclear myopathyMuscle SkeletalMolecular Biology030304 developmental biologyMice Knockout0303 health sciencesPTPLACell MembraneSkeletal muscleCell DifferentiationCell BiologyGeneral MedicineArticles[SDV.IDA] Life Sciences [q-bio]/Food engineeringmedicine.diseaseCongenital myopathyLysophosphatidylcholinemedicine.anatomical_structureLPCchemistryBiochemistryFemaleProtein Tyrosine Phosphatasescentronuclear myopathy;lpc;mufa;ptpla;vlcfa030217 neurology & neurosurgery
researchProduct

Depressive symptoms and muscle weakness: A two-way relation?

2018

The potential association between depressive symptoms and dynapenia – i.e. muscle weakness – is limited to few, mainly cross-sectional, studies. We use SHARE (Survey on Health, Ageing and Retirement in Europe) panel data to investigate whether the onset of dynapenia at 4-year follow-up can be explained by pre-existing (either at baseline, or at 2-year follow-up) depressive symptoms, or vice versa. Depressive symptoms were identified as a score of 4 or more on the 12-item EURO-D scale. Individuals were classified as affected by dynapenia if they had handgrip strength of &lt;20 kg for women and 30 kg for men. We estimate whether being affected by symptoms of depression at baseline or becoming…

Malemedicine.medical_specialtyAgingBiochemistry03 medical and health sciences0302 clinical medicineEndocrinologyRisk FactorsEpidemiologymedicineGeneticsHumansDepressive symptoms Dynapenia Europe SHARE030212 general & internal medicineMolecular BiologyDepressive symptomsDepression (differential diagnoses)AgedAged 80 and overMuscle WeaknessHand StrengthDepressive symptoms; Dynapenia; Europe; SHARE; Biochemistry; Aging; Molecular Biology; Genetics; Endocrinology; Cell BiologyDepressionbusiness.industryIncidenceDepressive symptomsMuscle weaknessCell BiologyEuropeCross-Sectional StudiesLogistic ModelsAgeingMultivariate AnalysisSHAREFemalemedicine.symptombusinessDynapenia030217 neurology & neurosurgeryFollow-Up StudiesClinical psychology
researchProduct

Sarcopenic obesity: definition, cause and consequences.

2008

PURPOSE OF REVIEW: Older obese persons with decreased muscle mass or strength are at special risk for adverse outcomes. We discuss potential pathways to muscle impairment in obese individuals and the consequences that joint obesity and muscle impairment may have on health and disability. Tantamount to this discussion is whether low muscle mass or, rather, muscle weakness should be used for the definition. RECENT FINDINGS: Excess energy intake, physical inactivity, low-grade inflammation, insulin resistance and changes in hormonal milieu may lead to the development of so-called 'sarcopenic obesity'. It was originally believed that the culprit of age-related muscle weakness was a reduction in…

Malemedicine.medical_specialtyAgingHealth StatusMedicine (miscellaneous)ComorbidityvanheneminenArticlesarcopeniaLow muscle massPhysical medicine and rehabilitationSDG 3 - Good Health and Well-beingClassification of obesityRisk FactorsmedicineHumansSarcopenic obesitysarkopeniaMuscle StrengthObesityExercise physiologyMuscle SkeletalExerciseAgedNutrition and Dieteticsbusiness.industryagingMuscle weaknessmedicine.diseaseComorbidityObesityMuscular AtrophyikääntyminenSarcopenia/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_beingFemalemedicine.symptombusinessCurrent Opinion in Clinical Nutrition and Metabolic Care
researchProduct

Ipsilateral facial weakness in upper medullary infarction-supranuclear or infranuclear origin?

1999

We describe two patients with upper medullary infarctions showing ipsilateral facial weakness and relative sparing of the upper facial muscles. Electrophysiological follow-up using transcranial magnetic stimulation of the motor cortex in combination with stimulation of the peripheral facial nerve disclosed a supranuclear (corticofacial) tract lesion in one patient and a partial nuclear/infranuclear intra-axial facial nerve lesion in another.

Malemedicine.medical_specialtyBrain Stem InfarctionsMedullary cavitymedicine.medical_treatmentFacial MusclesLesionReflexmedicineHumansAgedParesisMedulla OblongataMuscle Weaknessbusiness.industryMotor CortexFacial weaknessAnatomyMiddle AgedMagnetic Resonance ImagingFacial nerveElectric StimulationSurgeryTranscranial magnetic stimulationFacial Nervestomatognathic diseasesFacial musclesmedicine.anatomical_structureNeurologyNeurology (clinical)medicine.symptombusinessMotor cortexJournal of Neurology
researchProduct

Treatment of Duchenne muscular dystrophy with ciclosporin A: a randomised, double-blind, placebo-controlled multicentre trial.

2010

Summary Background Duchenne muscular dystrophy is a rare X-linked progressive disease characterised by loss of ambulation at about age 10 years, with death in early adulthood due to respiratory and cardiac insufficiency. Steroids are effective at slowing the progression of muscle weakness; however, their use is limited by side-effects, prompting the search for alternatives. We assessed the effect of ciclosporin A as monotherapy and in combination with intermittent prednisone for the treatment of ambulant patients with this disorder. Methods Our study was a parallel-group, placebo-controlled, double-blind, multicentre trial at trial sites of the German muscular dystrophy network, MD-NET, ove…

Malemedicine.medical_specialtyDuchenne muscular dystrophyMedizinPlacebolaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled trialDouble-Blind MethodlawPrednisoneInternal medicinemedicineHumansMuscular dystrophyChild030304 developmental biology0303 health sciencesbusiness.industryMuscle weaknessmedicine.diseaseCiclosporin3. Good healthSurgeryClinical trialMuscular Dystrophy DuchenneReview Literature as TopicTreatment OutcomeCyclosporineNeurology (clinical)medicine.symptombusiness030217 neurology & neurosurgerymedicine.drugThe Lancet. Neurology
researchProduct